Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

Launched by PROTEOCYTE DIAGNOSTICS INC. · Nov 4, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help predict the risk of oral cancer in patients who have suspicious-looking lesions in their mouths. Researchers are using a special test called the S100A7 immunohistochemistry signature-based assessment, or STRATICYTE, to see if it can effectively identify which lesions may develop into cancer. The study aims to find out if this method can help doctors make better decisions about monitoring or treating these lesions early on.

To participate in this trial, you need to have a lesion in your mouth that has been biopsied because doctors want to rule out the possibility of oral cancer. However, if you already have a diagnosis of oral squamous cell carcinoma (a type of mouth cancer), you won't be eligible for this study. If you join, you'll be part of a group that helps researchers understand how to better predict and manage the risk of oral cancer, which could lead to better outcomes for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma
• Exclusion Criteria:
• • Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy